drugset / Trial / NCT02265796

Ranolazine Among Unrevascularized Chronic Stable Angina Patients

NCT02265796

RandomizedSingle-groupQuadruple-blindTreatment

Summary

This is a prospective, double-blind, placebo-controlled, randomized, single-center (North Florida- South Georgia VA Medical Center) study. The study objective is to determine if ranolazine improves angina symptoms at 4 months compared with placebo among stable coronary artery disease patients who have demonstrable myocardial ischemia, but who do not undergo revascularization

Timeline

Start
2014-09
Primary completion
2016-05
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ranolazine Small molecule 1000 mg